JP2015522649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522649A5 JP2015522649A5 JP2015523571A JP2015523571A JP2015522649A5 JP 2015522649 A5 JP2015522649 A5 JP 2015522649A5 JP 2015523571 A JP2015523571 A JP 2015523571A JP 2015523571 A JP2015523571 A JP 2015523571A JP 2015522649 A5 JP2015522649 A5 JP 2015522649A5
- Authority
- JP
- Japan
- Prior art keywords
- depot
- buprenorphine
- precursor formulation
- precursor
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 238000009472 formulation Methods 0.000 claims 29
- 239000002243 precursor Substances 0.000 claims 24
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 16
- 229960001736 buprenorphine Drugs 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 6
- 238000013270 controlled release Methods 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 150000003462 sulfoxides Chemical class 0.000 claims 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 125000003892 C18 acyl group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000009115 maintenance therapy Methods 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 235000019149 tocopherols Nutrition 0.000 claims 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/558,463 | 2012-07-26 | ||
| US13/558,463 US20130190341A1 (en) | 2004-06-04 | 2012-07-26 | High bioavailability opioid formulations |
| US201361806185P | 2013-03-28 | 2013-03-28 | |
| US61/806,185 | 2013-03-28 | ||
| PCT/EP2013/065855 WO2014016428A1 (en) | 2012-07-26 | 2013-07-26 | Opioid formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522649A JP2015522649A (ja) | 2015-08-06 |
| JP2015522649A5 true JP2015522649A5 (enExample) | 2016-09-08 |
| JP6417327B2 JP6417327B2 (ja) | 2018-11-07 |
Family
ID=53487482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523571A Active JP6417327B2 (ja) | 2012-07-26 | 2013-07-26 | オピオイド製剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US12161640B2 (enExample) |
| JP (1) | JP6417327B2 (enExample) |
| CN (1) | CN109010255B (enExample) |
| AU (3) | AU2016244271B2 (enExample) |
| CL (1) | CL2015000197A1 (enExample) |
| CY (1) | CY1124016T1 (enExample) |
| DK (1) | DK2877155T3 (enExample) |
| EA (1) | EA034855B1 (enExample) |
| ES (1) | ES2837803T3 (enExample) |
| HK (1) | HK1221636A1 (enExample) |
| HR (1) | HRP20210068T1 (enExample) |
| HU (1) | HUE053273T2 (enExample) |
| IL (3) | IL296882A (enExample) |
| LT (1) | LT2877155T (enExample) |
| MX (2) | MX361873B (enExample) |
| MY (1) | MY189481A (enExample) |
| NZ (2) | NZ704012A (enExample) |
| PE (1) | PE20150672A1 (enExample) |
| PT (1) | PT2877155T (enExample) |
| SG (2) | SG10201703964TA (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2877155T (pt) | 2012-07-26 | 2020-12-18 | Camurus Ab | Formulações de opioides |
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| JP2020536955A (ja) * | 2017-10-06 | 2020-12-17 | ファウンドリー セラピューティクス， インコーポレイテッド | 治療剤の制御放出のための埋込み可能なデポー |
| EP3737433A1 (en) | 2018-01-08 | 2020-11-18 | Foundry Therapeutics, Inc. | Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
| WO2019221853A1 (en) | 2018-05-12 | 2019-11-21 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| EP3843710A1 (en) | 2018-08-28 | 2021-07-07 | Foundry Therapeutics, Inc. | Polymer implants |
| WO2020240018A1 (en) * | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
| EP4294367A4 (en) * | 2021-02-18 | 2025-02-12 | Navin Saxena Research and Technology Private Limited | Non-aqueous injectable composition for sustained release of buprenorphine and use thereof |
| CN117999079A (zh) * | 2021-08-20 | 2024-05-07 | 苏州恩华生物医药科技有限公司 | 一种包含塞纳布啡的药物组合物 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
| GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4610868A (en) | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| KR100225983B1 (ko) | 1992-10-26 | 1999-10-15 | 클라우스-디터 홈메리히, 디트리히 빌헬름 샤흐트 | 마이크로캡슐의 제조 방법 |
| JP3002702B2 (ja) | 1993-11-16 | 2000-01-24 | スカイファーム インコーポレーテッド | 活性物質の制御放出を有する小胞 |
| AU685262B2 (en) | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| ES2258495T3 (es) | 1994-04-08 | 2006-09-01 | Qlt Usa, Inc. | Composiciones de administracion liquida de farmacos. |
| SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| DE19536244A1 (de) | 1994-09-30 | 1996-04-04 | Juergen Dr Regenold | Pharmazeutische Zusammensetzung zur lokalen Applikation |
| FR2726762B1 (fr) | 1994-11-10 | 1997-01-17 | Oreal | Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention |
| US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
| AU702030B2 (en) | 1995-10-12 | 1999-02-11 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| SE9802528D0 (sv) | 1998-07-13 | 1998-07-13 | Gs Dev Ab | Bone tissue restoring composition |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| JP3952617B2 (ja) | 1998-12-11 | 2007-08-01 | 株式会社日立製作所 | 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒 |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| JP4659943B2 (ja) | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US20030003144A1 (en) | 2001-05-01 | 2003-01-02 | Keller Brian C. | Sustained release formulations for nifedipine, dextromethorphan, and danazol |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US20040022820A1 (en) | 2001-11-28 | 2004-02-05 | David Anderson | Reversed liquid crystalline phases with non-paraffin hydrophobes |
| PT2561860T (pt) | 2002-05-31 | 2018-05-08 | Titan Pharmaceuticals Inc | Dispositivo polimérico implantável para a libertação prolongada de buprenorfina |
| US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| AU2004229464A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| EP1682091B1 (en) | 2003-11-07 | 2017-03-29 | Camurus Ab | Compositions of lipids and cationic peptides |
| WO2005110360A2 (en) | 2004-05-18 | 2005-11-24 | Phares Pharmaceutical Research N.V. | Compositions for injection |
| EP1768650B1 (en) | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| GB0412530D0 (en) | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| ES2343641T3 (es) | 2005-01-14 | 2010-08-05 | Camurus Ab | Formulaciones bioadhesivas topicas. |
| WO2006075123A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
| WO2006077362A1 (en) | 2005-01-21 | 2006-07-27 | Camurus Ab | Pharmaceutical lipid compositions |
| US8097239B2 (en) | 2005-06-06 | 2012-01-17 | Camurus Ab | Controlled-release formulations |
| CN101217940B (zh) | 2005-06-06 | 2013-03-27 | 卡穆鲁斯公司 | Glp-1类似物制剂 |
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US20070265329A1 (en) | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
| MX337408B (es) | 2007-03-22 | 2016-03-03 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US8859579B2 (en) | 2008-03-21 | 2014-10-14 | Richard Andrew Sewell | Compostions and methods for preventing and/or treating disorders associated with cephalic pain |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| CN102307895A (zh) | 2008-12-04 | 2012-01-04 | 里兰斯坦福初级大学理事会 | 用于治疗或预防麻醉药停药症状的方法和组合物 |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US8975270B2 (en) | 2010-06-08 | 2015-03-10 | Rb Pharmaceuticals Limited | Injectable flowable composition comprising buprenorphine |
| GB2513267B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| CA2808237C (en) | 2010-09-03 | 2019-08-06 | Abbott Laboratories | High dose buprenorphine compositions and use as analgesic |
| CN103702662B (zh) | 2011-05-25 | 2018-07-20 | 卡穆鲁斯公司 | 控制释放肽制剂 |
| CN104093399B (zh) | 2011-12-05 | 2018-03-13 | 卡穆鲁斯公司 | 鲁棒性控释肽制剂 |
| PT2877155T (pt) | 2012-07-26 | 2020-12-18 | Camurus Ab | Formulações de opioides |
| AU2013294915C1 (en) | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| CN103142458B (zh) | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
| US11920160B2 (en) | 2013-02-22 | 2024-03-05 | Cedars-Sinai Medical Center | Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells |
| US9744163B2 (en) | 2013-03-15 | 2017-08-29 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US20140323517A1 (en) | 2013-04-30 | 2014-10-30 | Heron Therapeutics, Inc. | Compositions and methods for injection of a biodegradable polymer-based delivery system |
| JP6476658B2 (ja) | 2013-09-11 | 2019-03-06 | ソニー株式会社 | 画像処理装置および方法 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| GB201419091D0 (en) | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| US10471052B2 (en) | 2015-02-19 | 2019-11-12 | Mymd Pharmaceuticals, Inc. | Method of treating addictions to opioids |
| GB201516554D0 (en) | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
| CN108348881A (zh) | 2015-10-28 | 2018-07-31 | 托普索公司 | 乙苯脱氢成苯乙烯 |
| EP3863712A4 (en) | 2018-10-11 | 2022-07-20 | Indivior UK Limited | BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION |
-
2013
- 2013-07-26 PT PT137444949T patent/PT2877155T/pt unknown
- 2013-07-26 MY MYPI2015000187A patent/MY189481A/en unknown
- 2013-07-26 NZ NZ704012A patent/NZ704012A/en unknown
- 2013-07-26 JP JP2015523571A patent/JP6417327B2/ja active Active
- 2013-07-26 IL IL296882A patent/IL296882A/en unknown
- 2013-07-26 EA EA201590202A patent/EA034855B1/ru unknown
- 2013-07-26 ES ES13744494T patent/ES2837803T3/es active Active
- 2013-07-26 SG SG10201703964TA patent/SG10201703964TA/en unknown
- 2013-07-26 MX MX2015001033A patent/MX361873B/es active IP Right Grant
- 2013-07-26 HR HRP20210068TT patent/HRP20210068T1/hr unknown
- 2013-07-26 HU HUE13744494A patent/HUE053273T2/hu unknown
- 2013-07-26 NZ NZ735248A patent/NZ735248A/en unknown
- 2013-07-26 DK DK13744494.9T patent/DK2877155T3/da active
- 2013-07-26 CN CN201810814126.0A patent/CN109010255B/zh active Active
- 2013-07-26 SG SG11201500554XA patent/SG11201500554XA/en unknown
- 2013-07-26 MX MX2018015719A patent/MX387722B/es unknown
- 2013-07-26 PE PE2015000092A patent/PE20150672A1/es active IP Right Grant
- 2013-07-26 LT LTEP13744494.9T patent/LT2877155T/lt unknown
-
2015
- 2015-01-18 IL IL236762A patent/IL236762A0/en active IP Right Grant
- 2015-01-26 CL CL2015000197A patent/CL2015000197A1/es unknown
-
2016
- 2016-08-05 HK HK16109379.4A patent/HK1221636A1/en unknown
- 2016-10-13 AU AU2016244271A patent/AU2016244271B2/en active Active
-
2017
- 2017-12-20 AU AU2017279657A patent/AU2017279657B2/en active Active
-
2019
- 2019-02-13 AU AU2019200982A patent/AU2019200982B2/en active Active
-
2021
- 2021-01-13 CY CY20211100023T patent/CY1124016T1/el unknown
- 2021-12-20 IL IL289157A patent/IL289157A/en unknown
-
2023
- 2023-11-02 US US18/500,595 patent/US12161640B2/en active Active
- 2023-11-02 US US18/500,603 patent/US20240226091A9/en not_active Abandoned
-
2024
- 2024-10-28 US US18/928,649 patent/US12318379B2/en active Active
-
2025
- 2025-05-20 US US19/213,277 patent/US20260097031A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251413B1 (en) | Composition of injectable buprenorphine | |
| ES2876350T3 (es) | Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| HRP20210068T1 (hr) | Opioidne formulacije | |
| JP5966228B2 (ja) | アリピプラゾール組成物 | |
| MX361716B (es) | Formulaciones peptidicas de liberacion controlada. | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| JP2013508296A5 (enExample) | ||
| EA201592246A1 (ru) | Трансдермальная система доставки | |
| JP2015523407A5 (enExample) | ||
| MY160652A (en) | Pharmaceutical composition for oral administration | |
| WO2011112922A3 (en) | Co-crystals and pharmaceutical formulations comprising the same | |
| BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
| RU2017110076A (ru) | Фармацевтическая композиция и способы | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| RU2015109566A (ru) | НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА | |
| WO2011073408A3 (en) | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2016514706A5 (enExample) | ||
| MX2020003697A (es) | Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas. | |
| TR201000687A1 (tr) | Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar | |
| WO2009008004A3 (en) | Sustained release formulations of divalproex sodium | |
| WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
| JP2014513710A5 (enExample) | ||
| AR082806A1 (es) | Composicion farmaceutica estable |